BioLife Sciences Inc.
Other OTCTotal Valuation
BioLife Sciences Inc. carries a market capitalization of 156,683.00, placing it among publicly traded companies globally. Its enterprise value stands at 2.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 156,683.00 |
| Enterprise Value | 2.82M |
Share Statistics
BioLife Sciences Inc. currently has 5,249.00 shares outstanding.
| Shares Outstanding | 5,249.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
On an enterprise value basis, BioLife Sciences Inc. trades at an EV/EBITDA multiple of 15.42 and an EV/FCF ratio of 3.58. The EV/Sales ratio of 0.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.12 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.36 |
| EV / EBITDA | 15.42 |
| EV / EBIT | 32.12 |
| EV / FCF | 3.58 |
Financial Position
BioLife Sciences Inc. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.25 |
| Quick Ratio | 0.12 |
| Debt / Equity | -682.97 |
| Debt / EBITDA | 15.63 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -80.64 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BioLife Sciences Inc.'s stock has gained approximately 9900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioLife Sciences Inc. generated 7.84M in revenue and converted that into -2.68M in net income, yielding earnings per share of -692.23. EBITDA reached 182,872.00, while operating income came in at -116,860.00.
| Revenue | 7.84M |
| Gross Profit | 1.21M |
| Operating Income | -116,860.00 |
| Pretax Income | -2.68M |
| Net Income | -2.68M |
| EBITDA | 182,872.00 |
| EBIT | -116,860.00 |
| Earnings Per Share (EPS) | -692.23 |
Balance Sheet
BioLife Sciences Inc. holds 39,853.00 in cash and equivalents against 2.86M in total debt, resulting in a net debt position of 2.82M. Total book value stands at -5.13M, with working capital of -2.28M providing operational flexibility.
| Cash & Cash Equivalents | 39,853.00 |
| Total Debt | 2.86M |
| Net Debt | 2.82M |
| Equity (Book Value) | -5.13M |
| Book Value Per Share | -1,326.74 |
| Working Capital | -2.28M |
Cash Flow
BioLife Sciences Inc. produced -864,156.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -864,156.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -864,156.00 |
| FCF Per Share | -223.32 |
Margins
BioLife Sciences Inc. operates with a gross margin of 15.48, reflecting its pricing power and cost economics. The operating margin of -1.49 and net profit margin of -34.17 provide insight into operational efficiency.
| Gross Margin | 15.48 |
| Operating Margin | -1.49 |
| Pretax Margin | -34.17 |
| Profit Margin | -34.17 |
| EBITDA Margin | 2.33 |
Stock Splits
BioLife Sciences Inc.'s most recent stock split took place on July 23, 2018 with a 75:1 split ratio.
| Last Split Date | 7/23/2018 |
| Split Ratio | 75:1 |
Scores
BioLife Sciences Inc. posts an Altman Z-Score of -1.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.83 |